Oncolytics Biotech Inc. (ONCY)
- Previous Close
1.0200 - Open
1.0400 - Bid 0.9871 x 100
- Ask 1.0200 x 200
- Day's Range
1.0002 - 1.0400 - 52 Week Range
0.8800 - 3.3900 - Volume
139,680 - Avg. Volume
216,188 - Market Cap (intraday)
76.319M - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2900 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.77
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
www.oncolyticsbiotech.comRecent News: ONCY
Performance Overview: ONCY
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCY
Valuation Measures
Market Cap
77.83M
Enterprise Value
57.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.83%
Return on Equity (ttm)
-115.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.21M
Diluted EPS (ttm)
-0.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
29.6M
Total Debt/Equity (mrq)
4.91%
Levered Free Cash Flow (ttm)
-17.2M
Research Analysis: ONCY
Company Insights: ONCY
ONCY does not have Company Insights